Department of Cardiology, The first hospital of QinHuangDao, QinHuangDao.
Department of Critical Care Medicine, People's Hospital of Yangjiang, Yangjiang.
Coron Artery Dis. 2022 Nov 1;33(7):547-552. doi: 10.1097/MCA.0000000000001177. Epub 2022 Aug 9.
This study aimed to investigate the effect of intracoronary (IC) tirofiban compared to intravenously administered tirofiban in STEMI patients treated with PPCI.
This study included 180 STEMI patients who were underwent PPCI. Patients were randomized into an IC group ( n = 90) and intravenous (IV) group ( n = 90). During the procedure, the both groups were administered IC or IV injections of tirofiban, respectively, followed by an IV infusion of tirofiban for 24 hours. Changes in TIMI flow grading, TMP grade 3, Sum-STR two hours after the operation, the number of thrombus aspirations during the operation, myocardial enzyme, inflammatory factors,cardiac functional parameters, MACE and bleeding were investigated.
Following treatment, TIMI flow grading and TMP grade 3 were improved in the IC tirofiban compared to the IV group ( P = 0.022 and P = 0.014, respectively). Additionally, the Sum-STR two hours after operation, the incidence of MACEs, levels of AST, CRP, ESR, and TNI in the IC group was improved, compared with the IV group (all P < 0.05). Furthermore. Cardiac function including CO and LVEF were significantly improved in the IC group 6 months after discharge.
This study found that IC administration of tirofiban in patients with STEMI who underwent PPCI improved TIMI, TMP flow and cardiac function 6 months after discharge, and reduced CRP, ESR, and TNI. However, the incidence of bleeding between the two groups was comparable. These findings suggest that IC administration should be applied in certain acute STEMI patients.
本研究旨在探讨经皮冠状动脉介入治疗(PPCI)中冠状动脉内(IC)比伐芦定与静脉内给予比伐芦定对 ST 段抬高型心肌梗死(STEMI)患者的影响。
本研究纳入了 180 例接受 PPCI 的 STEMI 患者。患者随机分为 IC 组(n = 90)和静脉(IV)组(n = 90)。在手术过程中,两组分别给予 IC 或 IV 比伐芦定注射,随后静脉输注比伐芦定 24 小时。观察手术前后 TIMI 血流分级、TMP 分级 3、术后 2 小时 Sum-STR、术中血栓抽吸次数、心肌酶、炎症因子、心功能参数、主要不良心血管事件(MACE)和出血情况的变化。
治疗后,IC 比伐芦定组 TIMI 血流分级和 TMP 分级 3 较 IV 组改善(P = 0.022 和 P = 0.014)。此外,IC 组术后 2 小时 Sum-STR、MACE 发生率、AST、CRP、ESR 和 TNI 水平较 IV 组改善(均 P < 0.05)。此外,IC 组出院后 6 个月心脏功能包括 CO 和 LVEF 显著改善。
本研究发现,PPCI 治疗的 STEMI 患者 IC 给予比伐芦定可改善 TIMI、TMP 血流和心脏功能 6 个月后,并降低 CRP、ESR 和 TNI。然而,两组间出血发生率相当。这些发现表明,IC 给药应应用于某些急性 STEMI 患者。